Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bora Gurel

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 31, 2023
Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate CancerAntje Neeb, Ines Figueiredo, Bora Gurel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB DependenciesYi Liang, Sujeeve Jeganathan, Stefano Marastoni, et al.
The Journal of Clinical Investigation|April 1, 2026
Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancersAlec Paschalis, Ines Figueiredo, Denisa Bogdan, et al.
The Prostate|January 16, 2016
Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trialDanyelle A Winchester, Bora Gurel, Cathee Till, et al.
European Urology|July 13, 2020
Elucidating Durable Responses to Immune Checkpoint InhibitionPasquale Rescigno, Caterina Aversa, Mateus Crespo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive TumorsSophie Archer, Phillip M Brailey, Minjung Song, et al.
European Urology Oncology|March 12, 2026
An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate CancerRafael Grochot, Christina Guo, Suzanne Carreira, et al.
Cancer Research|October 23, 2022
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor ResistanceMarta J Llorca-Cardenosa, Lauren I Aronson, Dragomir B Krastev, et al.
Nature Medicine|June 27, 2025
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trialSusana Banerjee, Matthew G Krebs, Alastair Greystoke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2023
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)Alistair Ring, Lucy S Kilburn, Alex Pearson, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 31, 2023
Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate CancerAntje Neeb, Ines Figueiredo, Bora Gurel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB DependenciesYi Liang, Sujeeve Jeganathan, Stefano Marastoni, et al.
The Journal of Clinical Investigation|April 1, 2026
Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancersAlec Paschalis, Ines Figueiredo, Denisa Bogdan, et al.
The Prostate|January 16, 2016
Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trialDanyelle A Winchester, Bora Gurel, Cathee Till, et al.
European Urology|July 13, 2020
Elucidating Durable Responses to Immune Checkpoint InhibitionPasquale Rescigno, Caterina Aversa, Mateus Crespo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive TumorsSophie Archer, Phillip M Brailey, Minjung Song, et al.
European Urology Oncology|March 12, 2026
An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate CancerRafael Grochot, Christina Guo, Suzanne Carreira, et al.
Cancer Research|October 23, 2022
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor ResistanceMarta J Llorca-Cardenosa, Lauren I Aronson, Dragomir B Krastev, et al.
Nature Medicine|June 27, 2025
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trialSusana Banerjee, Matthew G Krebs, Alastair Greystoke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2023
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)Alistair Ring, Lucy S Kilburn, Alex Pearson, et al.
Pageof 8